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Purpose: The high-mobility group box −1 (HMGB1)/receptor for advanced glycation end products (RAGE)/osteopontin
(OPN)/early growth response-1 (Egr-1) pathway is involved in inflammation, angiogenesis, and fibrosis. We investigated
the  expression  of  the  components  of  this  pathway  in  proliferative  diabetic  retinopathy  (PDR)  and  proliferative
vitreoretinopathy (PVR) epiretinal membranes.
Methods: Nine active and 13 inactive membranes from patients with PDR and 21 membranes from patients with PVR
were studied by immunohistochemistry.
Results: In PDR membranes, vascular endothelial cells expressed HMGB1, RAGE, OPN, and Egr-1 in 21, 15, 20, and
16 membranes, respectively. Stromal cells expressed HMGB1, RAGE, OPN, and Egr-1 in 21, 20, 20, and 16 membranes,
respectively. Significant correlations were detected between the number of blood vessels expressing the panendothelial
cell marker CD34 and the number of blood vessels and stromal cells expressing HMGB1, RAGE, and OPN. The numbers
of blood vessels and stromal cells expressing CD34, HMGB1, RAGE, and OPN and stromal cells expressing Egr-1 were
significantly higher in active membranes than in inactive membranes. In PVR membranes, spindle-shaped myofibroblasts
expressing α-smooth muscle actin coexpressed HMGB1, RAGE, OPN, and Egr-1.
Conclusions: The HMGB1/RAGE/OPN/Egr-1 pathway may be involved in inflammatory, angiogenic and fibrotic
responses in proliferative vitreoretinal disorders.
Proliferative  diabetic  retinopathy  (PDR)  is  a  serious
complication  of  diabetes  mellitus  and  is  characterized  by
preretinal  neovascularization  and  the  development  of
fibrovascular  membranes  at  the  vitreoretinal  interface.
Formation of fibrovascular tissue often leads to severe visual
loss  due  to  vitreous  hemorrhage  and/or  tractional  retinal
detachment.  Proliferative  vitreoretinopathy  (PVR)  is  a
process of fibrocellular proliferation on either side of the
retina  that  may  complicate  rhegmatogenous  retinal
detachment. The formation and gradual contraction of these
membranes  causes  a  marked  distortion  of  the  retinal
architecture and results in complex retinal detachments that
are difficult to repair.
The pathogenesis of epiretinal membranes is still not well
understood, but inflammatory and immunologic processes are
known to be implicated [1-3]. In addition, strong evidence
indicates that chronic low-grade inflammation is implicated
in the pathogenesis of diabetic retinopathy. Diabetic retinal
vascular  leakage,  capillary  hypoperfusion,  and  endothelial
cell damage are associated with leukocyte recruitment and
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adhesion to the retinal vasculature, findings that correlate with
the increased expression of the retinal intercellular adhesion
molecule-1 (ICAM-1) and the leukocyte integrin CD18 [4].
High-mobility  group  box  −1  protein  (HMGB1)  or
amphoterin is a nonhistone DNA-binding nuclear protein that
is highly conserved during evolution and is present in most
eukaryotic cells, where it stabilizes nucleosome formation and
facilitates  transcription.  Necrotic  cell  death  can  result  in
passive leakage of HMGB1 from the cell, as the protein is then
no longer bound to DNA. In addition, HMGB1 can be actively
secreted by different cell types, including activated monocytes
and macrophages, mature dendritic cells, natural killer cells,
and endothelial cells. Extracellular HMGB1 functions as a
proinflammatory cytokine. In addition to advanced glycation
end products in diabetes, HMGB1 signals through the receptor
for advanced glycation end products (RAGE), a member of
the  immunoglobulin  superfamily  of  receptors,  leading  to
activation of the transcription factor nuclear factor kappa B
(NF-κB) and inducing the expression of various leukocyte
adhesion  molecules  and  proinflammatory  cytokines  and
chemokines  [5-8].  Several  studies  demonstrated  that  the
HMGB1/RAGE  signaling  axis  is  involved  in  angiogenic
[9-12] and fibrotic [13-16] disorders.
Osteopontin (OPN) is a phosphorylated acidic arginine-
glycine-aspartate (RGD)-containing glycoprotein that exists
both as an immobilized extracellular matrix component and
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508as a soluble, multifunctional, proinflammatory cytokine that
plays  important  roles  in  promoting  inflammation  [17,18],
tissue  remodeling,  fibrosis  [17,19-21],  and  angiogenesis
[22-24]. Many of these effects are mediated by the binding of
OPN to CD44 receptors and the surface integrin receptor
αvβ3 [22]. A recent study demonstrated that OPN is required
for  HMGB1  expression  by  fibroblasts  in  response  to  the
profibrotic cytokine transforming growth factor-β (TGF-β1)
[21].
Early growth response-1 (Egr-1) transcription factor, an
immediate early gene, belongs to the family of zinc finger
DNA-binding proteins. Normally, Egr-1 shows only a low
level  in  tissue  at  baseline,  but  is  rapidly  and  transiently
induced by many stimuli, including hypoxia, shear stress,
injury, growth factors, and cytokines. Egr-1 plays a key role
in orchestrating tissue response to acute injury by activating
the transcription of many proliferation-associated genes, such
as platelet-derived growth factor A and B, connective tissue
growth factor, vascular endothelial growth factor (VEGF),
TGF-β, tumor necrosis factor-α (TNF-α), ICAM-1, fibroblast
growth factor-2, insulin-like growth factor-2, interleukin-2
(IL-2) and Egr-1 itself [23,24]. Several studies demonstrated
that Egr-1 has a role in the induction and progression of
fibrosis [25-27] and angiogenesis [28].
In addition to NF-κB, which plays a central role in the
proinflammatory  signaling  stimulated  by  RAGE  ligands,
recent  studies  have  uncovered  the  novel  finding  that
upregulation  of  Egr-1  in  hypoxic  endothelial  cells  is
dependent on RAGE signaling [29]. In addition, HMGB1
enhanced Egr-1 expression and NF-κB nuclear translocation
in  vascular  endothelial  cells.  Anti-RAGE  antibody
significantly reduced HMGB1-induced expression of Egr-1
[30]. In addition, Liu et al. [31] demonstrated that Egr-1 and
OPN positively regulate expression of each other in a positive
feedback loop.
Given the key roles of the HMGB1/RAGE/OPN/Egr-1
signaling axis in inflammation, angiogenesis, and fibrosis, we
hypothesized  that  this  pathway  may  be  involved  in  the
pathogenesis of proliferative vitreoretinal disorders. To test
this hypothesis, we investigated the expression of HMGB1,
RAGE, OPN, and Egr-1 in the epiretinal membranes from
patients with PDR and PVR. The level of vascularization in
PDR  epiretinal  membranes  was  determined  by
immunodetection of the panendothelial cell marker CD34.
METHODS
Epiretinal  membrane  specimens:  Epiretinal  fibrovascular
membranes were obtained from 22 patients with PDR during
pars  plana  vitrectomy  for  the  repair  of  traction  retinal
detachment  or  combined  traction/rhegmatogenous  retinal
detachment.  Using  the  operating  microscope,  the  clinical
ocular findings were graded at the time of vitrectomy for the
presence or absence of visible new vessels on the retina or
optic disc. Patients with active PDR were graded as such on
the basis of visible new vessels on the retina or optic disc.
Their  absence  indicated  involuted  (inactive)  PDR.  Active
PDR  was  present  in  nine  patients  and  inactive  PDR  was
present in 13 patients. In addition, epiretinal membranes were
obtained from 21 eyes undergoing vitreoretinal surgery for the
treatment  of  retinal  detachment  complicated  by  PVR.
Membranes  were  fixed  in  10%  formalin  solution  and
embedded in paraffin. The study was conducted according to
the tenets of the Declaration of Helsinki, and informed consent
was obtained from all patients. The study was approved by the
Research Centre, College of Medicine, King Saud University.
Immunohistochemical staining: Endogenous peroxidase was
abolished with 2% hydrogen peroxide in methanol for 20 min,
and  nonspecific  background  staining  was  blocked  by
incubating the sections for 5 min in normal swine serum. For
OPN and RAGE detection, antigen retrieval was performed
by boiling the sections in 10 mM Tris-EDTA (EDTA) buffer
(pH 9; Sigma-Aldrich, Bornem, Belgium) for 30 min. For
CD34, α-smooth muscle actin (α-SMA), HMGB1, and Egr-1
detection,  antigen  retrieval  was  performed  by  boiling  the
sections  in  10  mM  citrate  buffer  (pH  6)  for  30  min.
Subsequently,  the  sections  were  incubated  with  the
monoclonal and polyclonal antibodies listed in Table 1. The
specificity of the antibodies used is indicated in Table 2. The
optimal working concentration and incubation time for the
antibodies were determined earlier in pilot experiments. For
RAGE,  a  second  step  was  introduced  using  1/20  rabbit
antigoat-peroxidase (Dako, Glostrup, Denmark) mixed with
1/10 normal human serum. The sections were then incubated
for 30 min with immunoglobulin conjugated to peroxidase-
labeled dextran polymer (EnVision Flex; Dako, Carpinteria,
CA). The reaction product was visualized by incubation for
10 min in 0.05 M acetate buffer at pH 4.9, containing 0.05%
3-amino-9-ethylcarbazole  (Sigma-Aldrich)  and  0.01%
hydrogen peroxide, resulting in bright-red immunoreactive
sites. The slides were then faintly counterstained with Harris
hematoxylin (Sigma-Aldrich).
Omission or substitution of the primary antibody with an
irrelevant antibody of the same species and staining with
chromogen alone were used as negative controls. Sections
from patients with colorectal carcinoma were used as positive
controls. The sections from the control patients were obtained
from patients treated at the University Hospital, University of
Leuven, Belgium, in full compliance with the tenets of the
Declaration of Helsinki.
Quantitation: Immunoreactive blood vessels and cells were
counted  in  five  representative  fields,  using  an  eyepiece-
calibrated grid in combination with the 40× objective. These
representative fields were selected based on the presence of
immunoreactive  blood  vessels  and  cells.  With  this
magnification and calibration, the cells present in an area of
0.33×0.22 mm were counted. Data were expressed as mean
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509values±standard deviation (SD) and analyzed by the Mann–
Whitney test. Pearson correlation coefficients were computed
to investigate the linear relationship between the variables
investigated. A p value less than 0.05 indicated statistical
significance.  BMDP  2007  Statistical  Package  (BMDP
Statistical  Software,  Los  Angeles,  CA)  was  used  for  the
statistical analysis.
RESULTS
Immunohistochemical analysis:
Proliferative  diabetic  retinopathy  membranes—No
staining  was  observed  in  the  negative  control  slides.  All
membranes  showed  blood  vessels  positive  for  the
panendothelial cell marker CD34 (Figure 1A), with a mean
number of 29.4±30.7 (range, 1–140). Immunoreactivity for
HMGB1  was  present  in  21  (95.5%)  membranes.  Strong
immunoreactivity for HMGB1 was noted in the nucleus and
cytoplasm  of  vascular  endothelial  cells  and  stromal  cells
(Figure 1B,C). The number of immunoreactive blood vessels
ranged from 0 to 82, with a mean number of 18.3±18.7. The
number of immunoreactive stromal cells ranged from 0 to 84,
with a mean number of 37.9±22.0. RAGE immunoreactivity
was  present  in  20  (91%)  membranes.  Strong  cytoplasmic
immunoreactivity  for  RAGE  was  noted  in  vascular
endothelial cells (Figure 1D,E) in 15 (68%) membranes, with
a  mean  number  of  19.6±14.7  (range,  0–60).  Strong
cytoplasmic  RAGE  immunoreactivity  was  also  noted  in
stromal cells (Figure 1D,E) in 20 (91%) membranes, with a
mean number of 40.2±30.7 (range, 0–80). In serial sections,
the  distribution  of  blood  vessels  expressing  HMGB1  was
similar to the distribution of blood vessels expressing RAGE.
Strong cytoplasmic immunoreactivity for OPN was present in
20 (91%) specimens. OPN immunoreactivity was noted in
vascular endothelial cells (Figure 1F), with a mean number of
12.5±10.9 (range, 0–30). OPN immunoreactivity was also
noted in stromal cells (Figure 1G), with a mean number of
24.4±22.9  (range,  0–75).  Immunoreactivity  for  Egr-1  was
noted in 16 (72.7%) membranes. Immunoreactivity for Egr-1
was  noted  in  the  nucleus  and  cytoplasm  of  vascular
endothelial cells and stromal cells (Figure 1H). The number
of immunoreactive blood vessels ranged from 0 to 30, with a
mean number of 8.7±7.4. The number of immunoreactive
stromal cells ranged from 0 to 60, with a mean number of
21.3±16.8.
Proliferative  vitreoretinopathy  membranes—No
straining  was  observed  in  the  negative  control  slides.  All
membranes  showed  spindle-shaped  myofibroblasts,
expressing a strong cytoplasmic immunoreactivity for α-SMA
(Figure 2A,B), with a mean number of 44.6±28.2 (range, 8–
120). Immunostaining for HMGB1 revealed spindle-shaped
cells expressing cytoplasmic immunoreactivity (Figure 2C,D)
in 20 (95.2%) membranes, with a mean number of 40.9±24.7
(range, 0–90). Spindle-shaped cells expressing cytoplasmic
immunoreactivity for RAGE (Figure 2E) were noted in 12
(85.7%) of the 14 membranes stained for RAGE, with a mean
TABLE 1. MONOCLONAL AND POLYCLONAL ANTIBODIES USED IN THIS STUDY.
Primary antibody Dilution Incubation time Source*
Anti-CD34 (Clone My10) (mc) 1/50 60 min BD Biosciences
Anti- a-Smooth muscle actin (Clone 1A4) (mc) 1/200 60 min Dako
Anti-HMGB1 (Catalogue No. ab77302) (mc) 1/20 60 min Abcam
Anti-RAGE (Catalogue No. ab20558) (pc) 1/100 60 min Abcam
Anti-Osteopontin (Catalogue No. ab8448) (pc) 1/500 60 min Abcam
Anti-Egr-1 (Catalogue No. AHP1939) (pc) 1/50 60 min AbD Serotec
*Location of manufacturers: BD Biosciences, San Jose, CA; Dako, Glostrup, Denmark; Abcam, Cambridge, UK; AbD Serotec,
Oxford, UK mc=monoclonal ; pc=polyclonal HMGB1=high-mobility group box −1; RAGE=receptor for advanced glycation
end products; Egr-1=early growth response-1.
TABLE 2. SPECIFICITY OF THE ANTIBODIES USED IN THE STUDY.
Primary antibody Specificity
Anti-CD34 Reactive with the CD34 antigen
Anti- α-Smooth
muscle actin
Labels a-Smooth muscle actin
Anti-HMGB1 Reacts with the full length human HMGB1 protein
Anti-RAGE Recognizes amino acid sequence 385–399 of human RAGE
Anti-Osteopontin Recognizes the full length osteopontin protein, as well as the C-terminal fragments of both thrombin and matrix
metalloproteinase (MMP)-cleaved osteopontin. This antibody recognizes the 32 kDa MMP-cleaved fragment, but not the
40 kDa N-terminal fragment.
Anti-Egr-1 Recognizes human EGR1, a 57.5 kDa nuclear protein belonging to the EGR family of C2H2-type zinc-finger proteins.
        HMGB1=high-mobility group box −1; RAGE=receptor for advanced glycation end products; Egr-1=early growth response-1
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510Figure 1. Proliferative diabetic retinopathy epiretinal membranes. A: Immunohistochemical staining of panendothelial cell marker CD34
shows blood vessels positive for CD34 (arrows; original magnification 40×). Immunohistochemical staining of high-mobility group box −1
(HMGB1). Low power (B; original magnification 40×) and high power (C; original magnification 100×) showing vascular endothelial (arrows)
and stromal (arrowheads) cells expressing strong immunoreactivity to HMGB1. Immunohistochemical staining of receptor for advanced
glycation end products (RAGE). Low-power (D; original magnification 40×) and high-power (E; original magnification 100×) showing
vascular endothelial (arrows) and stromal (arrowheads) cells expressing strong immunoreactivity to RAGE. Immunohistochemical staining
of osteopontin (OPN) showing vascular endothelial cells (arrows; F) and stromal cells (arrowheads; G) expressing strong immunoreactivity
to OPN (original magnification 100×). Immunohistochemical staining of early growth response-1 showing immunoreactivity in vascular
endothelial (arrows) and stromal (arrowheads) cells (H; original magnification 100×).
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511number of 55±29.1 (range, 0–120). Immunostaining for OPN
revealed  spindle-shaped  cells  expressing  cytoplasmic
immunoreactivity (Figure 2F) in all membranes, with a mean
number of 21.2±16.5 (range, 8–70). Immunoreactivity for
Egr-1 was noted in the nucleus and cytoplasm of spindle-
shaped cells (Figure 2G,H) in 16 (94.1%) of the 17 membranes
stained for Egr-1, with a mean number of 23.1±18.7 (range,
0–80). In serial sections, the distribution of myofibroblasts
expressing α-SMA was similar to the distribution of cells
expressing HMGB1, RAGE, OPN, and Egr-1.
Correlations  and  relationship  with  proliferative  diabetic
retinopathy  activity:  The  mean  number  of  blood  vessels
expressing CD34, HMGB1, RAGE, and OPN, and stromal
cells  expressing  HMGB1,  RAGE,  OPN,  and  Egr-1  was
significantly higher in membranes from patients with active
PDR than in membranes from patients with inactive PDR
(Table 3). Table 4 shows the Pearson correlation coefficients
between the numbers of the studied variables.
DISCUSSION
To gain a better understanding of the cellular and molecular
processes  underlying  the  pathogenesis  of  proliferative
vitreoretinal  disorders,  we  examined  the  expression  of
HMGB1, RAGE, OPN, and Egr-1 in epiretinal membranes
from patients with PDR and PVR. The following four findings
were demonstrated: (1) Vascular endothelial cells and stromal
cells  in  PDR  epiretinal  membranes  expressed  HMGB1,
RAGE, OPN, and Egr-1. (2) Significant correlations were
observed between the number of blood vessels expressing the
panendothelial  cell  marker  CD34  in  PDR  epiretinal
membranes and the number of blood vessels and stromal cells
expressing HMGB1, RAGE, and OPN. (3) The number of
blood vessels expressing CD34, HMGB1, RAGE, and OPN
and the number of stromal cells expressing HMGB1, RAGE,
OPN, and Egr-1 in membranes from patients with active PDR
were  significantly  higher  than  that  in  membranes  from
patients with inactive PDR. (4) HMGB1, RAGE, OPN, and
Egr-1 proteins were specifically localized in myofibroblasts
in PVR epiretinal membranes. Taken together, our findings
suggest a role for the HMGB1/RAGE/OPN/Egr-1 signaling
axis in the inflammatory, angiogenic and fibrotic responses in
proliferative  vitreoretinal  disorders  via  autocrine  and/or
paracrine mechanisms, resulting in a positive feedback loop
that may contribute to the progression of PDR and PVR.
Sustained  proinflammatory  responses  in  diabetic
retinopathy are often associated with angiogenesis [2-4]. The
causal relationship between inflammation and angiogenesis is
now  widely  accepted  [5].  An  emerging  issue  in  diabetic
retinopathy  research  is  the  focus  on  the  mechanistic  link
between chronic, low-grade inflammation and angiogenesis.
Recently,  HMGB1  has  been  identified  as  a  novel
proinflammatory  cytokine  [5-8]  that  exhibits  angiogenic
[9-12]  and  fibrogenic  [13-16]  effects.  Several  studies
demonstrated that RAGE mediates the inflammatory [6-8],
angiogenic [9,32], and fibrogenic [15] activities of HMGB1.
Another interesting role of HMGB1 in neovascularization is
its ability to attract endothelial progenitor cells to sites of
tissue injury and tumors to improve neovascularization in a
RAGE-dependent manner [11]. HMGB1 binding to RAGE
activates  key  cell-signaling  pathways  such  as  mitogen-
activated protein kinases and NF-κB [5-8].
In  the  present  study,  HMGB1  and  RAGE  were
colocalized in vascular endothelial cells and stromal cells in
PDR  epiretinal  membranes.  Increased  vascular  HMGB1
expression was demonstrated in diabetic animals [33], and
recently  it  was  demonstrated  that  hyperglycemia-induced
reactive oxygen species production increases the expression
of HMGB1 and RAGE in endothelial cells [34]. In addition,
stimulation of human endothelial cells by TNF-α induced
relocation of HMGB1 from the nucleus to the cytoplasm and
the subsequent release of HMGB1 [35]. Activation of the
HMGB1/RAGE  signaling  axis  is  important  in  promoting
proinflammatory pathways which are considered to play an
important  role  in  diabetes-induced  retinal  vascular
inflammation. HMGB1 activates human endothelial cells to
upregulate the expression of RAGE and adhesion molecules,
such as ICAM-1, vascular cell adhesion molecule-1, and E-
selectin,  and  to  release  TNF-α,  granulocyte  colony-
stimulating factor, IL-8, and monocyte chemotactic protein-1,
and to increase neutrophil adhesion. This proinflammatory
phenotype was mediated by the activation of NF-κB, and it
was RAGE-dependent, since it was inhibited by antibodies
directed  toward  RAGE  [6-8].  In  agreement  with  in  vitro
studies, systemic administration of the soluble form of RAGE
inhibits blood-retinal barrier breakdown, leukostasis, and the
expression of ICAM-1 in the retinas of diabetic animals [36].
RAGE  also  represents  an  important  mediator  of  vascular
oxidative stress in diabetes due to RAGE-dependent increased
expression  of  NADPH  oxidase  subunits  [33].  Therefore,
recently, RAGE has been implicated in the pathogenesis of
various diabetic complications [37].
The key cellular mediator of fibrosis is the myofibroblast,
a cell type different from quiescent fibroblasts. These are
contractile cells, characterized by the expression of α-SMA,
and their presence is a marker of progressive disease. They
have  the  capacity  to  produce  several  extracellular  matrix
components, including collagen, resulting in fibrosis [38]. In
the  present  study,  we  demonstrated  that  strong
immunoreactivities for HMGB1 and RAGE were specifically
localized  in  α-SMA-positive  myofibroblasts  in  PVR
epiretinal  membranes.  This  is  in  agreement  with  studies
showing  overexpression  of  HMGB1  and  RAGE  in  other
fibrotic  disorders  such  as  systemic  sclerosis  fibrotic  skin
lesions  [14],  idiopathic  pulmonary  fibrosis  [13],  and
bleomycin-induced lung fibrosis [16]. It is also in agreement
with  studies  showing  that  increased  HMGB1  and  RAGE
expression was detected in fibroblasts in fibrotic skin lesions
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512Figure  2.  Proliferative  vitreoretinopathy  epiretinal  membranes.  Immunohistochemical  staining  of  α-smooth  muscle  actin  showing
immunoreactivity in spindle-shaped myofibroblasts (arrows; A) and (B; original magnification 100×). Immunohistochemical staining of high-
mobility group box −1 (HMGB1). Low-power (C; original magnification 40×) and high-power (D; original magnification 100×) showing
spindle-shaped cells expressing cytoplasmic immunoreactivity to HMGB1 (arrows). Immunohistochemical staining of the receptor for
advanced glycation end products (RAGE) showing spindle-shaped cells expressing cytoplasmic immunoreactivity to RAGE (arrows; E;
original magnification 40×). Immunohistochemical staining of osteopontin showing strong cytoplasmic immunoreactivity in spindle-shaped
cells (arrows; F; original magnification 40×). Immunohistochemical staining of early growth response-1 showing spindle-shaped cells
expressing cytoplasmic immunoreactivity (arrows; G; original magnification 40×) and cells expressing nuclear immunoreactivity (arrows;
H; original magnification 100×).
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513from patients with systemic sclerosis [14]. In a previous study,
Pachydaki  et  al.  [39]  reported  expression  of  RAGE  and
HMGB1 in epiretinal membranes; however, they interpreted
the cells that expressed RAGE and HMGB1 to be glial cells.
In vitro studies demonstrated that HMGB1 stimulated the
proliferation  and  migration  of  fibroblasts  through  the
activation  of  RAGE  [13,15].  In  addition,  exposure  of
epithelial cells to HMGB1 resulted in the transition from an
epithelial to myofibroblast-like phenotype, with a significant
increase in the mesenchymal markers α-SMA and vimentin
[16]. Recently, Arimura et al. [40] demonstrated that HMGB1
stimulated the migration of human retinal pigment epithelial
cells,  suggesting  that  HMGB1  may  serve  to  promote  the
formation of PVR.
Several  studies  reported  that  the  proinflammatory
cytokine OPN plays a role in the development of diabetic
vascular complications. Retinal endothelial cells under high-
glucose conditions expressed increased levels of OPN and
αvβ3 integrin [41]. OPN expression is enhanced in human
diabetic  arteries  [41]  and  in  arteries  of  animal  models  of
diabetes  [42].  Increased  renal  OPN  expression  was  also
reported in human diabetic kidneys [43] and in experimental
diabetic  nephropathy  [17].  Increased  OPN  expression  in
tubular epithelial cells of the cortex is implicated in interstitial
fibrosis  in  experimental  diabetic  nephropathy  [17].  In
addition, vitreous OPN levels are increased in patients with
diabetic  retinopathy  [44].  In  vitro  and  in  vivo  studies
demonstrated  that  OPN  is  an  important  angiogenic  factor
[45-47]. OPN also increased VEGF expression in endothelial
cells [45]. Anti-αvβ3 abrogated the effects of OPN on human
endothelial  cells  [45,46].  In  the  present  study,  OPN  was
localized in vascular endothelial cells and stromal cells in
PDR  epiretinal  membranes.  In  a  previous  study,  we
demonstrated  that  αvβ3  integrin  was  expressed  in  PDR
epiretinal  membranes  and  was  specifically  localized  in
vascular  endothelial  cells  and  stromal  cells  [48].  These
findings suggest that OPN can bind to αvβ3 integrin in PDR
epiretinal membranes and enhance angiogenesis.
OPN  is  required  for  the  activation,  migration,
proliferation, and differentiation of fibroblasts into α-SMA-
expressing  myofibroblasts  [19-21].  In  addition,  OPN  is
upregulated  in  several  fibrotic  diseases  [17,19,20].  In  the
present  study,  OPN  was  specifically  localized  in
myofibroblasts in PVR epiretinal membranes. In a previous
report,  we  demonstrated  that  CD44,  a  cell-surface  matrix
adhesion  receptor  for  OPN,  was  highly  expressed  on
myofibroblast in PVR epiretinal membranes [49], suggesting
that these myofibroblasts are primed to bind to OPN.
In  the  present  study,  we  confirmed  that  Egr-1  was
localized in vascular endothelial cells and stromal cells in
PDR epiretinal membranes. Previous reports demonstrated
that  Egr-1  is  activated  in  endothelial  cells  by  many
proangiogenic  growth  factors,  such  as  VEGF  and
angiopoietin-1 [28]. Egr-1 was found to play an important role
in angiopoietin-1-induced migration, proliferation, and the
capillary-like  tube  formation  of  endothelial  cells  [28].  In
addition, insulin or glucose upregulated Egr-1 in vascular
endothelial cells, suggesting that Egr-1 may play a role in the
development of vascular complications from diabetes [50].
Several studies demonstrated that the transcription factor
Egr-1 has a functional role in the induction and progression
of fibrosis. Bleomycin-induced scleroderma in the mouse was
accompanied  by  increased  Egr-1  nuclear  expression  in
lesional fibroblasts [25]. In this animal model, development
of fibrosis in the skin and lungs was markedly attenuated in
Egr-1  null  mice.  Furthermore,  skin-wound  healing  was
impaired, and skin fibroblasts lacking Egr-1 showed reduced
migration  and  myofibroblast  transdifferentiation  in  vitro
[26]. Egr-1 was also found to be upregulated by TGF-β [25]
and  insulin-like  growth  factor  binding  protein-5  [27]  in
fibroblasts, and to mediate the stimulation of extracellular
matrix components transcription and fibrosis elicited by these
TABLE 3. MEAN NUMBERS IN RELATION TO TYPE OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR).
Variable Active PDR (n=9;
Mean±SD)
Inactive PDR (n=13;
Mean±SD)
p-value (Mann–
Whitney test)
Blood vessels expressing CD34 54.1±35.0 12.2±7.0 <0.001*
Blood vessels expressing HMGB1 29.2±23.6 9.3±5.0 0.009*
Cells expressing HMGB1 49.0±19.7 29.5±20.5 0.046*
Blood vessels expressing RAGE 26.8±15.1 8.3±2.4 0.011*
Cells expressing RAGE 63.0±30.6 21.5±13.6 0.003*
Blood vessels expressing OPN 20.6±11.4 5.9±3.9 0.004*
Cells expressing OPN 43.0±21.1 9.2±8.4 <0.001*
Blood vessels expressing Egr-1 10.9±8.3 4.8±3.3 0.081
Cells expressing Egr-1 28.9±16.4 11.4±12.1 0.028*
        *Statistically significant at 5% level of significance. Abbreviations: HMGB1=high-mobility group box −1; RAGE=receptor for
        advanced glycation end products; OPN=osteopontin; Egr-1=early growth response-1.
Molecular Vision 2011; 17:508-518 <http://www.molvis.org/molvis/v17/a58> © 2011 Molecular Vision
514T
A
B
L
E
 
4
.
 
P
E
A
R
S
O
N
 
C
O
R
R
E
L
A
T
I
O
N
 
C
O
E
F
F
I
C
I
E
N
T
S
V
a
r
i
a
b
l
e
B
l
o
o
d
 
v
e
s
s
e
l
s
e
x
p
r
e
s
s
i
n
g
 
C
D
3
4
B
l
o
o
d
 
v
e
s
s
e
l
s
e
x
p
r
e
s
s
i
n
g
H
M
G
B
1
C
e
l
l
s
e
x
p
r
e
s
s
i
n
g
H
M
G
B
1
B
l
o
o
d
 
v
e
s
s
e
l
s
e
x
p
r
e
s
s
i
n
g
R
A
G
E
C
e
l
l
s
e
x
p
r
e
s
s
i
n
g
R
A
G
E
B
l
o
o
d
 
v
e
s
s
e
l
s
e
x
p
r
e
s
s
i
n
g
O
P
N
C
e
l
l
s
e
x
p
r
e
s
s
i
n
g
O
P
N
B
l
o
o
d
 
v
e
s
s
e
l
s
e
x
p
r
e
s
s
i
n
g
 
E
g
r
-
1
B
l
o
o
d
 
v
e
s
s
e
l
s
 
e
x
p
r
e
s
s
i
n
g
 
H
M
G
B
1
 
r
0
.
9
4
6
 
 
 
 
 
 
 
p
<
0
.
0
0
1
*
 
 
 
 
 
 
 
C
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
H
M
G
B
1
 
r
0
.
6
2
5
0
.
6
2
1
 
 
 
 
 
 
p
0
.
0
0
2
*
0
.
0
0
2
*
 
 
 
 
 
 
B
l
o
o
d
 
v
e
s
s
e
l
s
 
e
x
p
r
e
s
s
i
n
g
 
R
A
G
E
 
r
0
.
9
6
9
0
.
9
5
1
0
.
6
0
2
 
 
 
 
 
p
<
0
.
0
0
1
*
<
0
.
0
0
1
*
0
.
0
2
3
*
 
 
 
 
 
C
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
R
A
G
E
 
r
0
.
4
7
8
0
.
4
1
0
.
5
7
6
0
.
3
3
2
 
 
 
 
p
0
.
0
3
3
*
0
.
0
9
1
0
.
0
1
0
*
0
.
2
2
6
 
 
 
 
B
l
o
o
d
 
v
e
s
s
e
l
s
 
e
x
p
r
e
s
s
i
n
g
 
O
P
N
 
r
0
.
7
2
2
0
.
6
5
5
0
.
4
9
6
0
.
7
3
0
.
2
6
6
 
 
 
p
<
0
.
0
0
1
*
0
.
0
0
2
*
0
.
0
3
1
*
0
.
0
0
3
*
0
.
2
8
6
 
 
 
C
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
O
P
N
 
r
0
.
7
5
6
0
.
6
8
7
0
.
8
4
5
0
.
7
6
9
0
.
6
4
7
0
.
6
7
5
 
 
p
<
0
.
0
0
1
*
0
.
0
0
1
*
<
0
.
0
0
1
*
0
.
0
0
1
*
0
.
0
0
4
*
0
.
0
0
4
 
 
B
l
o
o
d
 
v
e
s
s
e
l
s
 
e
x
p
r
e
s
s
i
n
g
 
E
g
r
-
1
 
r
0
.
5
2
4
0
.
6
8
3
0
.
6
5
4
0
.
6
0
3
0
.
2
7
4
0
.
3
9
4
0
.
3
8
2
 
p
0
.
0
5
5
0
.
0
1
0
*
0
.
0
1
5
*
0
.
0
2
9
*
0
.
3
4
4
0
.
1
6
3
0
.
1
7
7
 
C
e
l
l
s
 
e
x
p
r
e
s
s
i
n
g
 
E
g
r
-
1
 
r
0
.
5
2
4
0
.
2
1
3
0
.
5
4
1
0
.
0
7
5
0
.
4
9
9
0
.
0
5
6
0
.
4
4
0
.
2
9
1
p
0
.
3
4
9
0
.
4
4
6
0
.
0
3
7
*
0
.
8
0
8
0
.
0
4
9
*
0
.
8
3
8
0
.
0
8
8
0
.
3
1
2
 
 
 
 
 
 
 
 
 
 
*
S
t
a
t
i
s
t
i
c
a
l
l
y
 
s
i
g
n
i
f
i
c
a
n
t
 
a
t
 
5
%
 
l
e
v
e
l
 
o
f
 
s
i
g
n
i
f
i
c
a
n
c
e
.
 
W
h
e
r
e
 
t
h
e
 
r
o
w
 
a
n
d
 
c
o
l
u
m
n
 
m
e
e
t
 
i
s
 
t
h
e
 
c
o
r
r
e
l
a
t
i
o
n
 
c
o
e
f
f
i
c
i
e
n
t
 
(
r
)
 
a
n
d
 
t
h
e
 
p
-
v
a
l
u
e
 
(
p
)
 
f
o
r
 
t
h
e
 
t
w
o
 
 
 
 
 
 
 
 
 
 
v
a
r
i
a
b
l
e
s
.
H
M
G
B
1
=
h
i
g
h
-
m
o
b
i
l
i
t
y
 
g
r
o
u
p
 
b
o
x
 
−
1
;
 
R
A
G
E
=
r
e
c
e
p
t
o
r
 
f
o
r
 
a
d
v
a
n
c
e
d
 
g
l
y
c
a
t
i
o
n
 
e
n
d
 
p
r
o
d
u
c
t
s
;
 
O
P
N
=
o
s
t
e
o
p
o
n
t
i
n
;
 
E
g
r
-
1
=
e
a
r
l
y
 
g
r
o
w
t
h
 
r
e
s
p
o
n
s
e
-
1
.
Molecular Vision 2011; 17:508-518 <http://www.molvis.org/molvis/v17/a58> © 2011 Molecular Vision
515growth  factors  [29,30].  In  addition,  Egr-1  levels  were
increased in vivo in lung tissues of patients with idiopathic
pulmonary fibrosis [27] and in lesional skin and lung from
patients with scleroderma [25]. Increased expression of Egr-1
in these fibrotic disorders was localized to fibroblasts [25,
27]. Consistent with these studies, we demonstrated that Egr-1
was  expressed  in  myofibroblasts  in  PVR  epiretinal
membranes,  suggesting  that  Egr-1  might  be  one  of  the
mechanisms responsible for the maintenance of remodeling
and pathological fibrosis in this fibrotic disorder.
It  should  be  mentioned,  however,  that  this  study
inevitably has some inherent limitations, because it is based
on only immunohistochemical detection of these molecules in
epiretinal membranes. Several investigations to look at the
level of these molecules in vitreous samples from diabetic
patients will be required. However, our findings suggest that
the  HMGB1/RAGE/OPN/Egr-1  signaling  pathway  is
involved  in  mediating  inflammation,  angiogenesis,  and
fibrosis in proliferative vitreoretinal disorders. This pathway
may be a novel therapeutic target to inhibit progression of
PDR and PVR.
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